Clinical Cancer Research Highlights of This Issue 5145 SPECIAL FEATURES CCR Translations

Transcription

Clinical Cancer Research Highlights of This Issue 5145 SPECIAL FEATURES CCR Translations
Clinical Cancer Research
Table of
Contents
October 15, 2014 Volume 20 Number 20
5207
Highlights of This Issue 5145
SPECIAL FEATURES
Emanuele Zucca, Francesco Bertoni,
Barbara Vannata, and Franco Cavalli
CCR Translations
5147
5217
Blocking Immunosuppressive Checkpoints for
Glioma Therapy: The More the Merrier!
Maria G. Castro, Gregory J. Baker, and
Pedro R. Lowenstein
See related article, p. 5290
CCR New Strategies
5240
New Strategies in Ovarian Cancer: Translating
the Molecular Complexity of Ovarian Cancer
into Treatment Advances
Molecular Pathways: Myeloid Complicity in
Cancer
CANCER THERAPY: CLINICAL
Ingunn M. Stromnes, Philip D. Greenberg, and
Sunil R. Hingorani
5255
CCR Focus
The Lymphoma Medicine Cabinet
Putting the Clinical and Biological
Heterogeneity of Non-Hodgkin Lymphoma
into Context
Owen A. O0 Connor and Kensei Tobinai
5182
PERSONALIZED MEDICINE AND IMAGING
5265
Precision Treatment of Distinct Molecular
Subtypes of Diffuse Large B-cell Lymphoma:
Ascribing Treatment Based on the Molecular
Phenotype
Gene Signature–Guided Dasatinib Therapy in
Metastatic Breast Cancer
Lajos Pusztai, Stacy Moulder, Mehmet Altan,
Danielle Kwiatkowski, Vicente Valero,
Naoto T. Ueno, Francisco J. Esteva, Rony Avritscher,
Yuan Qi, Lewis Strauss, Gabriel N. Hortobagyi,
Christos Hatzis, and W. Fraser Symmans
Kieron Dunleavy, Mark Roschewski, and
Wyndham H. Wilson
5194
A Phase I Study of the First-in-Class
Antimitochondrial Metabolism Agent,
CPI-613, in Patients with Advanced
Hematologic Malignancies
Timothy S. Pardee, King Lee, John Luddy,
Claudia Maturo, Robert Rodriguez, Scott Isom,
Lance D. Miller, Kristin M. Stadelman,
Denise Levitan, David Hurd, Leslie R. Ellis,
Robin Harrelson, Megan Manuel, Sarah Dralle,
Susan Lyerly, and Bayard L. Powell
Susan E. Bates
5173
Changing the Paradigms of Treatment in
Peripheral T-cell Lymphoma: From Biology to
Clinical Practice
Owen A. O’Connor, Govind Bhagat,
Karthik Ganapathi, Martin Bjerregaard Pedersen,
Francesco D’Amore, Dejan Radeski, and
Susan E. Bates
Molecular Pathways
5172
Are We Nearing an Era of Chemotherapy-Free
Management of Indolent Lymphoma?
Emmanuel Bachy and Gilles Salles
Joyce Liu and Ursula A. Matulonis
5157
Human T-cell Lymphotropic Virus Type
I–Associated Adult T-cell Leukemia–
Lymphoma: New Directions in Clinical
Research
Kunihiro Tsukasaki and Kensei Tobinai
5226
5150
Emerging Role of Infectious Etiologies in the
Pathogenesis of Marginal Zone B-cell
Lymphomas
New Paradigms in Mantle Cell Lymphoma: Is It
Time to Risk-Stratify Treatment Based on the
Proliferative Signature?
Martin Dreyling, Simone Ferrero, Niklas Vogt, and
Wolfram Klapper on behalf of the European Mantle
Cell Lymphoma Network
iii
Table of Contents
5272
Development and Validation of a Gene
Profile Predicting Benefit of Postmastectomy
Radiotherapy in Patients with High-Risk
Breast Cancer: A Study of Gene Expression in
the DBCG82bc Cohort
5311
Stefan Peter, Edyta Borkowska, Ross M. Drayton,
Callum P. Rakhit, Aidan Noon, Wei Chen, and
James WF Catto
Trine Tramm, Hayat Mohammed, Simen Myhre,
Marianne Kyndi, Jan Alsner,
Anne-Lise Børresen-Dale, Therese Sørlie,
Arnoldo Frigessi, and Jens Overgaard
5281
5322
Pharmacogenomic Modeling of Circulating
Tumor and Invasive Cells for Prediction of
Chemotherapy Response and Resistance in
Pancreatic Cancer
Mismatch Repair Status and BRAF Mutation
Status in Metastatic Colorectal Cancer
Patients: A Pooled Analysis of the CAIRO,
CAIRO2, COIN, and FOCUS Studies
Sabine Venderbosch, Iris D. Nagtegaal,
Tim S. Maughan, Christopher G. Smith,
Jeremy P. Cheadle, David Fisher, Richard Kaplan,
Philip Quirke, Matthew T. Seymour,
Susan D. Richman, Gerrit A. Meijer, Bauke Ylstra,
Danielle A.M. Heideman, Anton F.J. de Haan,
Cornelis J.A. Punt, and Miriam Koopman
Kenneth H. Yu, Mark Ricigliano, Manuel Hidalgo,
Ghassan K. Abou-Alfa, Maeve A. Lowery,
Leonard B. Saltz, Joseph F. Crotty, Kristen Gary,
Brandon Cooper, Rena Lapidus, Mariola Sadowska,
and Eileen M. O0 Reilly
5331
CANCER THERAPY: PRECLINICAL
5290
Identification of Differentially Expressed
Long Noncoding RNAs in Bladder Cancer
Smoking and Risk of Low- and High-Grade
Prostate Cancer: Results from the REDUCE
Study
Tammy Ho, Lauren E. Howard, Adriana C. Vidal,
Leah Gerber, Daniel Moreira, Madeleine McKeever,
Gerald Andriole, Ramiro Castro-Santamaria, and
Stephen J. Freedland
Durable Therapeutic Efficacy Utilizing
Combinatorial Blockade against IDO, CTLA4, and PD-L1 in Mice with Brain Tumors
Derek A. Wainwright, Alan L. Chang, Mahua Dey,
Irina V. Balyasnikova, Chung Kwon Kim,
Alex Tobias, Yu Cheng, Julius W. Kim, Jian Qiao,
Lingjiao Zhang, Yu Han, and Maciej S. Lesniak
See related commentary, p. 5147
CORRECTION
5339
Correction: Targeting miR21 Inhibits In Vitro
and In Vivo Multiple Myeloma Cell Growth
BIOLOGY OF HUMAN TUMORS
5302
Overdetection of Recurrence after Radical
Prostatectomy: Estimates Based on Patient
and Tumor Characteristics
Jing Xia, Bruce J. Trock, Roman Gulati,
Leslie Mallinger, Matthew R. Cooperberg,
Peter R. Carroll, H. Ballentine Carter, and
Ruth Etzioni
AC icon indicates Author Choice
CME icon indicates that this article is available for continuing medical education credit at http://cme.aacrjournals.org
For more information please visit www.aacrjournals.org
iv
Table of Contents
ABOUT THE COVER
The cover shows the expression of long noncoding RNAs in normal and malignant bladder urothelium
as detected by microarray. Unsupervised hierarchical clustering reveals discrimination of normal,
low-grade and high-grade malignant tissues. For details, see the article by Peter and colleagues on
page 5311 of this issue.
v

Similar documents

Hodgkin Lymphoma Market 10 Year Epidemiology Forecasts in 7 Major Markets

Hodgkin Lymphoma Market 10 Year Epidemiology Forecasts in 7 Major Markets The Hodgkin’s lymphoma treatment market is set to increase more than fourfold from $316 million in 2014 to $1.4 billion by 2024, representing a Compound Annual Growth Rate (CAGR) of 16%. Hodgkin’s lymphoma (HL), or Hodgkin’s disease, is a malignancy which involves the lymph nodes and the lymphatic system. HL is a relatively rare type of cancer, accounting for 12% of all lymphomas and 0.6% of all new cancer cases, but overall prognosis is very good.

More information

Global Follicular Lymphoma Industry Size, Segmentation, Demand Forecast Report Up To 2015: Radiant Insights, Inc

Global Follicular Lymphoma Industry Size, Segmentation, Demand Forecast Report Up To 2015: Radiant Insights, Inc Follicular Lymphoma - Pipeline Review, H2 2015', provides an overview of the Follicular Lymphoma's therapeutic pipeline. Read More @ http://www.radiantinsights.com/research/follicular-lymphoma-pipeline-review-h2-2015

More information

AIDS Related Primary CNS Lymphoma Market Analysis, Segments, Growth and Value Chain 2016-2026

AIDS Related Primary CNS Lymphoma Market Analysis, Segments, Growth and Value Chain 2016-2026 Acquired immunodeficiency syndrome (AIDS) is a viral disease of immune system caused by the infection of human immunodeficiency virus (HIV). Primary central nervous system lymphoma (PCNSL) is a primary intracranial tumor occurs mostly in patients suffering from severe immunosuppression specifically AIDS. The pathogen responsible for primary CNS lymphoma is Epstein-Barr virus. AIDS associated primary CNS lymphoma diffuses large-cell lymphoma of B-cell which usually occurs in brain or spinal cord. Patients suffering from CNS lymphoma complain about lethargy, headache, neurologic symptoms and signs and changes in mental status. For diagnosing AIDS associated primary CNS lymphoma, Computed Tomography (CT) scan or Magnetic Resonance Imaging (MRI) is performed. Biopsy diagnosis is also performed to confirm the results as the lesions reported in MRI and CT scan sometimes generate confusion between toxoplasmosis, progressive multifocal leukoencephalopathy (PML) lesions and lymphoma.

More information

Follicular Lymphoma Market Treatment, Analysis, Outlook and Pipeline Review, H1 2016

Follicular Lymphoma Market Treatment, Analysis, Outlook and Pipeline Review, H1 2016 Global Markets Direct's, 'Follicular Lymphoma - Pipeline Review, H1 2016', provides an overview of the Follicular Lymphoma pipeline landscape Visit Us @ http://www.radiantinsights.com/research/follicular-lymphoma-pipeline-review-h1-2016

More information

Indolent Lymphoma Treatment Market : Global Industry Analysis and Forecast 2016 - 2022

Indolent Lymphoma Treatment Market : Global Industry Analysis and Forecast 2016 - 2022 Indolent lymphoma treatment is most common cancer observed in the lymphatic system and can be treated successfully. The factors which contribute to drive the indolent lymphoma market are geriatric population and lifestyle. In today’s world people have addictions to alcohol, tobacco and drugs, obesity is one of the major cause of various disorders thus the risks for such disorders are high. The mortality ratio is quite low as compared to treatment facilities available a few years back. Clinical approvals and safety regulations laid by FDA and regulatory bodies are some restraints for this market, but many other drugs are into clinical trials and will soon be available for use.

More information

Global Diffuse Large B-Cell Lymphoma Market Size, Growth, Trends & Forecast Report To 2015: Radiant Insights, Inc

Global Diffuse Large B-Cell Lymphoma Market Size, Growth, Trends & Forecast Report To 2015: Radiant Insights, Inc 'Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2015', provides an overview of the Diffuse Large B-Cell Lymphoma's therapeutic pipeline. Read More @ http://www.radiantinsights.com/research/diffuse-large-b-cell-lymphoma-pipeline-review-h2-2015

More information

Latest Report - Global B-Cell Non-Hodgkin Lymphoma Industry Size, Growth Trends, 2015: Radiant Insights, Inc

Latest Report - Global B-Cell Non-Hodgkin Lymphoma Industry Size, Growth Trends, 2015: Radiant Insights, Inc 'B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H2 2015', provides an overview of the B-Cell Non-Hodgkin Lymphoma's therapeutic pipeline.. Visit Us @ http://www.radiantinsights.com/research/b-cell-non-hodgkin-lymphoma-pipeline-review-h2-2015

More information